Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
ceftazidime pentahydrate
Pfizer Australia Pty Ltd
ceftazidime pentahydrate
Registered
HOSPIRA™ CEFTAZIDIME POWDER FOR INJECTION ceftazidime (as pentahydrate) (_kef-TAZ-e-deem_) CONSUMER MEDICINE INFORMATION _ Date of Dispensing_ _Consumer Name _ _ Pharmacist Name _ _Consumer Address _ _ Pharmacist Address _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about HOSPIRA™ Ceftazidime Powder for Injection. It does not contain all the available information. It does not take the place of talking to your doctor and pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given HOSPIRA™ Ceftazidime Powder for Injection against the benefits this medicine is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET IN A SAFE PLACE. You may need to read it again. WHAT HOSPIRA™ CEFTAZIDIME POWDER FOR INJECTION IS USED FOR Ceftazidime is an antibiotic used to treat infections in different parts of the body caused by bacteria. Ceftazidime will not work against infections caused by viruses such as colds or the flu. Ceftazidime belongs to a group of antibiotics called cephalosporins (cef-a-loe-SPOR-ins). These antibiotics work by killing the bacteria that are causing your infection. Your doctor may have prescribed ceftazidime for another reason. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY CEFTAZIDIME HAS BEEN PRESCRIBED FOR YOU. This medicine is available only with a doctor’s prescription. BEFORE YOU ARE GIVEN HOSPIRA™ CEFTAZIDIME POWDER FOR INJECTION _WHEN YOU MUST NOT BE _ _GIVEN IT _ _ _ HOSPIRA™ CEFTAZIDIME POWDER FOR INJECTION SHOULD NOT BE GIVEN TO YOU IF YOU HAVE AN ALLERGY TO: • ceftazidime • other cephalosporins • any of the ingredients listed at the end of this leaflet. • lignocaine Symptoms of an allergic reaction may include: • shortness of breath, wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • rash, itching or hives on the skin. CEFTAZIDIME SHOULD NOT BE GIVEN TO YOU IF YOU HAVE HA Lugege kogu dokumenti
Product Information - Australia HOSPIRA™ CEFTAZIDIME, POWDER FOR INJECTION NAME OF THE MEDICINE Ceftazidime (as ceftazidime pentahydrate) CAS No. 78439-06-2 Molecular Weight: 636.6 Molecular formula: C 22 H 22 N 6 O 7 S 2 , 5H 2 O Chemical name: (6 _R_ ,7 _R_ )-7-[[(2 _Z_ )-2-(2-Aminothiazol-4-yl)-2-[(1-carboxy-1 methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)methyl]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylate pentahydrate. DESCRIPTION Hospira™ Ceftazidime Powder for Injection is a cephalosporin antibiotic for use by injection only. It is supplied as a white to cream coloured crystalline powder in vials containing 1 g and 2 g ceftazidime (as pentahydrate) with sodium carbonate anhydrous (117 mg per gram of ceftazidime). On the addition of Water for Injections, Hospira™ Ceftazidime Powder for Injection dissolves with effervescence to produce a light yellow to amber coloured solution for injection. Ceftazidime pentahydrate is slightly soluble in water and in methanol, practically insoluble in acetone and in ethanol (96 per cent). It dissolves in acid and alkali solutions. Ceftazidime pentahydrate decomposes at about 150 °C . Ceftazidime penthahydrate is hygroscopic and crystalline in nature . No potential polymorphism is reported. Hospira™ Ceftazidime Powder for Injection contains approximately 51 mg (2.17 mEq) of sodium per gram of ceftazidime. 116 mg ceftazidime pentahydrate is equivalent to 100 mg ceftazidime anhydrous. For laboratory tests associated with ceftazidime administration, ceftazidime pentahydrate should be used. PHARMACOLOGY PHARMACOKINETICS Absorption of ceftazidime after oral administration is negligible, therefore Hospira™ Ceftazidime Powder for Injection is intended for parenteral use only. Version 2.0 Page 1 Product Information - Australia In humans, after a single intramuscular administration of 500 mg and 1 g, mean peak serum levels of 18 and 37 mg/L respectively are achieved at 1 hour, falling to 8 and 2 mg/L and 20 and 5 mg/L at four and eight hours respectively for Lugege kogu dokumenti